tegafur has been researched along with Angiogenesis, Pathologic in 19 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib plus metronomic tegafur/uracil therapy can induce tumor stabilization in advanced hepatocellular carcinoma (HCC) patients." | 9.15 | Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. ( Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Hsu, CY; Hu, FC; Shen, YC; Shih, TT; Wei, SY; Yu, CW, 2011) |
| "Sorafenib plus metronomic tegafur/uracil therapy can induce tumor stabilization in advanced hepatocellular carcinoma (HCC) patients." | 5.15 | Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. ( Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Hsu, CY; Hu, FC; Shen, YC; Shih, TT; Wei, SY; Yu, CW, 2011) |
| "Metronomic chemotherapy using the 5-FU prodrug uracil-tegafur (UFT) and cyclophosphamide (CTX) was previously shown to only modestly delay primary tumor growth, but nevertheless markedly suppressed the development of micro-metastasis in an orthotopic breast cancer xenograft model, using the metastatic variant of the MDA-MB-231 cell line, 231/LM2-4." | 3.91 | Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion. ( Cruz-Muñoz, W; Hileeto, D; Kerbel, RS; Man, S; Muñoz, R; Viloria-Petit, A; Wood, GA; Xu, P, 2019) |
| " Using a murine dorsal air sac (DAS) assay, we have previously shown that UFT and its metabolites, gamma-hydroxybutyric acid (GHB) and 5-fluorouracil (5-FU), inhibited the angiogenesis induced by murine renal cell carcinoma." | 3.71 | gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. ( Aoyagi, K; Basaki, Y; Chikahisa, L; Hashimoto, A; Miyadera, K; Okabe, S; Wierzba, K; Yamada, Y; Yonekura, K, 2001) |
| "The prognosis for hepatocellular carcinoma with extrahepatic metastasis or vascular invasion is very poor." | 2.47 | [A successful case of systemic chemotherapy followed by liver resection for advanced hepatocellular carcinoma with highly vascular invasion and multiple pulmonary metastases]. ( Kakisaka, T; Kamachi, H; Kamiyama, T; Matsushita, M; Mizukami, T; Nakanishi, K; Tahara, M; Taniguchi, M; Todo, S; Yokoo, H, 2011) |
| " Recently, we showed that the combination of oral metronomic S-1 dosing with oxaliplatin (l-OHP)-containing PEG-coated "neutral" liposomes exerted excellent antitumor activity." | 1.38 | Combination therapy with metronomic S-1 dosing and oxaliplatin-containing PEG-coated cationic liposomes in a murine colorectal tumor model: synergy or antagonism? ( Abu Lila, AS; Doi, Y; Ichihara, M; Ishida, T; Kiwada, H; Okada, T, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (10.53) | 18.2507 |
| 2000's | 9 (47.37) | 29.6817 |
| 2010's | 8 (42.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Muñoz, R | 1 |
| Hileeto, D | 1 |
| Cruz-Muñoz, W | 1 |
| Wood, GA | 1 |
| Xu, P | 2 |
| Man, S | 2 |
| Viloria-Petit, A | 1 |
| Kerbel, RS | 2 |
| Ferdous, T | 1 |
| Harada, K | 2 |
| Kin, T | 1 |
| Harada, T | 1 |
| Ueyama, Y | 1 |
| Tsuji, W | 1 |
| Ishiguro, H | 1 |
| Tanaka, S | 1 |
| Takeuchi, M | 1 |
| Ueno, T | 1 |
| Toi, M | 1 |
| Chen, FG | 1 |
| Wang, JJ | 1 |
| Xue, Q | 1 |
| Tang, TC | 1 |
| Lee, CR | 1 |
| Hsu, CY | 1 |
| Shen, YC | 1 |
| Yu, CW | 1 |
| Hsu, C | 1 |
| Hu, FC | 1 |
| Hsu, CH | 1 |
| Chen, BB | 1 |
| Wei, SY | 1 |
| Cheng, AL | 1 |
| Shih, TT | 1 |
| Mizukami, T | 1 |
| Kamiyama, T | 1 |
| Nakanishi, K | 1 |
| Taniguchi, M | 1 |
| Yokoo, H | 1 |
| Tahara, M | 1 |
| Kakisaka, T | 1 |
| Kamachi, H | 1 |
| Matsushita, M | 1 |
| Todo, S | 1 |
| Higuchi, M | 1 |
| Suzuki, H | 1 |
| Shio, Y | 1 |
| Satoh, Y | 1 |
| Kitamura, M | 1 |
| Gotoh, M | 1 |
| Abu Lila, AS | 1 |
| Okada, T | 1 |
| Doi, Y | 1 |
| Ichihara, M | 1 |
| Ishida, T | 1 |
| Kiwada, H | 1 |
| Nakajima, Y | 1 |
| Gotanda, T | 1 |
| Uchimiya, H | 1 |
| Furukawa, T | 1 |
| Haraguchi, M | 1 |
| Ikeda, R | 1 |
| Sumizawa, T | 1 |
| Yoshida, H | 2 |
| Akiyama, S | 1 |
| Tanaka, F | 1 |
| Yanagihara, K | 1 |
| Otake, Y | 1 |
| Miyahara, R | 1 |
| Wada, H | 1 |
| Masaki, T | 1 |
| Ohkawa, S | 1 |
| Amano, A | 1 |
| Ueno, M | 1 |
| Miyakawa, K | 1 |
| Tarao, K | 1 |
| Kawashima, Y | 1 |
| Sato, M | 1 |
| Yonekura, K | 5 |
| Basaki, Y | 5 |
| Chikahisa, L | 4 |
| Okabe, S | 4 |
| Hashimoto, A | 5 |
| Miyadera, K | 4 |
| Wierzba, K | 3 |
| Yamada, Y | 5 |
| Shibata, J | 2 |
| Murakami, K | 1 |
| Fukushima, M | 1 |
| Aoyagi, K | 3 |
| Nishimura, G | 1 |
| Yanoma, S | 1 |
| Satake, K | 1 |
| Ikeda, Y | 1 |
| Taguchi, T | 1 |
| Nakamura, Y | 1 |
| Hirose, F | 1 |
| Tsukuda, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of Sorafenib Plus Tegafur/Uracil for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma[NCT00464919] | Phase 2 | 50 participants (Anticipated) | Interventional | 2007-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for tegafur and Angiogenesis, Pathologic
| Article | Year |
|---|---|
[A successful case of systemic chemotherapy followed by liver resection for advanced hepatocellular carcinoma with highly vascular invasion and multiple pulmonary metastases].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Combined Modality Therapy; Drug Combinat | 2011 |
Angiogenesis and the efficacy of postoperative administration of UFT in pathologic stage I non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, | 2004 |
2 trials available for tegafur and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Orally administered S-1 suppresses circulating endothelial cell counts in metastatic breast cancer patients.
Topics: 4-Butyrolactone; Administration, Oral; Adult; Aged; Antigens, CD34; Antimetabolites, Antineoplastic; | 2014 |
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2011 |
15 other studies available for tegafur and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cycloph | 2019 |
Efficacy of schedule-dependent metronomic S-1 chemotherapy in human oral squamous cell carcinoma cells.
Topics: Administration, Metronomic; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carc | 2013 |
[Inhibition of angiogenesis of LCI-D20 hepatocellular carcinoma by metronomic chemotherapy of S-1].
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Drug Combinations; F | 2009 |
Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; | 2010 |
[A case of long-term survival after resection of aortic arch for locally advanced non-small cell lung cancer with induction chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta, Thoracic; Carcinoma, Non-Small-Cell Lung; Cis | 2011 |
Combination therapy with metronomic S-1 dosing and oxaliplatin-containing PEG-coated cationic liposomes in a murine colorectal tumor model: synergy or antagonism?
Topics: Administration, Metronomic; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy P | 2012 |
Inhibition of metastasis of tumor cells overexpressing thymidine phosphorylase by 2-deoxy-L-ribose.
Topics: Animals; Apoptosis; Deoxyribose; Drug Therapy, Combination; Interleukin-8; Liver Neoplasms; Male; Mi | 2004 |
Noninvasive assessment of tumor vascularity by contrast-enhanced ultrasonography and the prognosis of patients with nonresectable pancreatic carcinoma.
Topics: Adult; Aged; Contrast Media; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcit | 2005 |
S-1 inhibits tumorigenicity and angiogenesis of human oral squamous cell carcinoma cells by suppressing expression of phosphorylated Akt, vascular endothelial growth factor and fibroblast growth factor-2.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Combinati | 2007 |
UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice.
Topics: 4-Butyrolactone; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cel | 1999 |
[Anti-metastatic and anti-angiogenic activity of UFT in a lung spontaneous metastasis model in mice].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Kidney Neoplasms; Lu | 1999 |
[Anti-angiogenic activities of UFT and its metabolites, GHB and GBL, in the dorsal air sac (DAS) model in mice].
Topics: 4-Butyrolactone; Animals; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kidney Neo | 2000 |
An experimental model of tumor dormancy therapy for advanced head and neck carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antioxidan | 2000 |
UFT and its metabolites inhibit cancer-induced angiogenesis. Via a VEGF-related pathway.
Topics: Air Sacs; Animals; Antineoplastic Combined Chemotherapy Protocols; Biological Assay; Carcinoma, Rena | 2000 |
gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma; Carc | 2001 |